ArticleZoological research2020
MOSPD2 is a receptor mediating the LEAP-2 effect on monocytes/macrophages in a teleost,
Article in Zoological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- zDHHC20b-mediated TRIF palmitoylation drives infection-induced necroptosis through the TRIF-RIPK3 axis in teleost monocytes/macrophages.Zoological research · 2026Article
- LEAP2 triggers retromer-mediated membrane trafficking of MOSPD2 to promote chemotaxis in teleost monocytes/macrophages.Zoological research · 2025Article
- Molecular Characterization of the Liver-Expressed Antimicrobial Peptide 2 (LEAP2) fromAnimals : an open access journal from MDPI · 2025Article
- Identification and characterisation of LEAP2 from Chinese spiny frogs (Quasipaa spinosa) with antimicrobial and macrophage activation properties.BMC veterinary research · 2025Article
- Peptide with Dual Roles in Immune and Metabolic Regulation: Liver-Expressed Antimicrobial Peptide-2 (LEAP-2).Molecules (Basel, Switzerland) · 2025Review
- Palmitoylation-mediated NLRP3 inflammasome activation in teleosts highlights evolutionary divergence in immune regulation.Zoological research · 2025Article
- Serum LEAP2 Levels Across the Spectrum of Metabolic Dysfunction-Associated Fatty Liver Disease: A Potential Noninvasive Biomarker for Severity Stratification.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Structure-activity relationships of the intramolecular disulphide bonds in LEAP2, an antimicrobial peptide from Acrossocheilus fasciatus.BMC veterinary research · 2024Article
- The anti-inflammatory role of zDHHC23 through the promotion of macrophage M2 polarization and macrophage necroptosis in large yellow croaker (Frontiers in immunology · 2024Article
- Prior exposure to ciprofloxacin disrupts intestinal homeostasis and predisposes ayu (Zoological research · 2022Article
- Involvement of POMC neurons in LEAP2 regulation of food intake and body weight.Frontiers in endocrinology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver-expressed antimicrobial peptide 2 (LEAP-2) is a cationic peptide that plays an important role in a host's innate immune system. We previously demonstrated that mudskipper (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.